MF
Frias, Miguel
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Rethinking HDL functionality: the emerging roles of sphingosine-1-phosphate and anti-apolipoprotein A1autoantibodies |  | 2025 | 5 | 54 | |||
| People living with HIV display increased anti-apolipoprotein A1 auto-antibodies, inflammation, and kynurenine metabolites : a case–control study | Frontiers in cardiovascular medicine | | 2024 | 117 | 46 | ||
| Ferritin : a biomarker requiring caution in clinical decision | Diagnostics | | 2024 | 101 | 155 | ||
| Associations between high-density lipoprotein particle’s proteome, subfractions and autoantibodies against apolipoprotein A1 in HIV patients | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 10 | 0 | |||
| Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic | Journal of neurology, neurosurgery and psychiatry | | 2023 | 272 | 228 | ||
| High antibody titers against apolipoprotein-A1 in NAFLD: a possible link between fatty liver disease and CVD? | 90th European Atherosclerosis Society (EAS) congress | 2022 | 163 | 0 | |||
| Sphingosine‐1‐phosphate as a key player of insulin secretion induced by high‐density lipoprotein treatment | Physiological reports | | 2021 | 260 | 181 | ||
| Autoantibodies directed against apolipoprotein-A1 as a potential contributor to Non-Alcoholic Fatty Liver Disease | 89th Europen Society of Atherosclerosis (EAS) | 2021 | 147 | 0 | |||
| Antibodies against apolipoprotein a-1 as disruptors of cellular cholesterol homeostasis promoting foam cell formation | 88th EAS (European Atherosclerosis Society) Congress | 2020 | 69 | 0 | |||
| High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases | Metabolism, clinical and experimental |  | 2020 | 189 | 0 | ||
| Auto-antibodies against apolipoprotein a-1 block cancer cells proliferation and induce apoptosis | Oncotarget | | 2020 | 174 | 133 | ||
| HDL protects against myocardial ischemia reperfusion injury via miR-34b and miR-337 expression which requires STAT3 | PLOS ONE | | 2019 | 293 | 210 | ||
| Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation | Journal of clinical medicine | | 2019 | 242 | 202 | ||
| P5343 - The presence of anti-apolipoprotein A1 autoantibodies is associated with a pro-atherogenic profile in HIV-infected patients | ESC Congress 2019 together with World Congress of Cardiology | 2019 | 122 | 0 | |||
| ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1 | Journal of Immunological Methods | | 2019 | 394 | 1 | ||
| Humoral immunity against HDL particle: a new perspective in cardiovascular diseases? | Current Pharmaceutical Design | | 2019 | 277 | 0 | ||
| Separation of blood microsamples by exploiting sedimentation at the microscale | Scientific Reports | | 2018 | 501 | 248 | ||
| Sphingosine-1-phosphate reduces ischaemia-reperfusion injury by phosphorylating the gap junction protein Connexin43 | Cardiovascular research | | 2016 | 700 | 6 | ||
| Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection | Arteriosclerosis, Thrombosis, and Vascular Biology | | 2016 | 628 | 1 | ||
| Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury | PloS one | | 2015 | 680 | 269 | ||
| CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes | Endocrinology | | 2015 | 671 | 1 | ||
| High density lipoproteins and ischemia reperfusion injury: the therapeutic potential of HDL to modulate cell survival pathways | Advances in experimental medicine and biology | 2014 | 552 | 0 | |||
| HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity | Atherosclerosis | | 2013 | 555 | 0 | ||
| JAK-STAT signaling and myocardial glucose metabolism | JAK-STAT | | 2013 | 501 | 1 | ||
| Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/reperfusion injury | Journal of Molecular and Cellular Cardiology | | 2013 | 654 | 0 | ||
| HDLs protect pancreatic β-cells against ER stress by restoring protein folding and trafficking | Diabetes | | 2012 | 640 | 0 | ||
| The natural cardioprotective particle HDL modulates connexin43 gap junction channels | Cardiovascular research | | 2012 | 679 | 4 | ||
| Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins | Current signal transduction therapy | 2012 | 574 | 0 | |||
| Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection | Cardiovascular drugs and therapy | | 2012 | 638 | 0 | ||
| High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway | JAK-STAT | | 2012 | 620 | 372 | ||
| Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis | Cardiovascular research | | 2010 | 601 | 0 | ||
| Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate | Cardiovascular research | | 2009 | 563 | 0 | ||
| The Prostaglandin E2 – Stat3 connection in hypertrophic and antiapoptotic responses in ventricular cardiomyocytes | | 2008 | 1,013 | 396 | |||
| The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis | Cardiovascular research | | 2008 | 653 | 0 |
